
PRME Stock Forecast & Price Target
PRME Analyst Ratings
Bulls say
Prime Medicine Inc. is advancing its innovative genetic medicine development, with strong prospects indicated by preclinical success in its program PM577 for Wilson Disease, which demonstrates targeted gene correction in animal models and a pathway to enhance patient outcomes. The company's focus on the alpha-1 antitrypsin deficiency (AATD) program underlines its potential as a best-in-class solution in a market lacking disease-modifying treatments, presenting significant commercial opportunities. Additionally, upcoming regulatory milestones, including potential approvals and partnerships, alongside positive peer valuations, suggest a promising upside for Prime Medicine's stock over the next 12-15 months.
Bears say
The financial outlook for Prime Medicine Inc is adversely affected by uncertainties surrounding the regulatory approval of its key products, PM577 and PM647. Despite the company's promising preclinical results, the risk remains that even successful endpoints may not lead to regulatory acceptance, resulting in potential downward revisions of financial projections. Furthermore, any complexities or delays in the regulatory pathway could further exacerbate the situation, negatively impacting the company's financial projections and overall valuation.
This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares